Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Oda

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
Transplantation Proceedings|April 1, 1996
A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar?K Morozumi, K Sugito, A Oda, et al.
Leukemia|April 9, 2011
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cellsJ Asano, A Nakano, A Oda, et al.
Leukemia|October 5, 2016
Expansion of Th<sub>1</sub>-like Vγ<sub>9</sub>Vδ<sub>2</sub>T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acidT Harada, H Miki, Q Cui, et al.
Leukemia|May 3, 2014
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myelomaM Hiasa, J Teramachi, A Oda, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
Transplantation Proceedings|April 1, 1996
A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar?K Morozumi, K Sugito, A Oda, et al.
Leukemia|April 9, 2011
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cellsJ Asano, A Nakano, A Oda, et al.
Leukemia|October 5, 2016
Expansion of Th<sub>1</sub>-like Vγ<sub>9</sub>Vδ<sub>2</sub>T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acidT Harada, H Miki, Q Cui, et al.
Leukemia|May 3, 2014
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myelomaM Hiasa, J Teramachi, A Oda, et al.
Pageof 16